In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Rosetta Genomics nets $26.2mm through IPO on Nasdaq

Executive Summary

Rosetta Genomics, which uses micro-ribonucleic acid (miRNA) to treat and diagnose diseases, netted $26.2mm (including the overallotment) in its initial public offering on Nasdaq of 4.3mm ordinary shares at $7 each, slightly below its planned price range of $7.50-8.50. In September 2006, the company announced its intention to sell 3mm shares at $11-13 apiece.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies